Research Associate II - Formulation (Contract)

Responsibilities

• Collaborate with Research to identify and prepare preclinical formulations.
• Perform supportive stability studies and develop instructions to enable reproducible formulation preparation.
• Design and execution of pre-formulation studies to determine the chemical and physical properties of our small molecule drug candidates.
• Analytical support for our drug products which include in-process testing of powder blends and final product testing of tablets.

Qualifications

• 1-2 years of hands-on experience working in a laboratory with analytical instrumentation, preferably with previous experience in pre-formulation and formulation development.
• Experience with HPLC in the development of analytical methods for the analysis and characterization of small molecule samples is a plus.
• Good oral and written communications skills.
• Enjoy working with others in a fast-paced, multidisciplinary environment.
• Self-motivated and organized, enjoy scientific investigation and thinks proactively to identify issues and develop solutions.

Benefits

• The anticipated salary range for candidates who will work in our South San Francisco location is between $35-$45 per hour.
• The final salary offered to a successful candidate will be dependent on several factors that may include but are not limited to the title, type and length of experience within the job, type and length of experience within the industry, education, etc.

Pay

• The anticipated salary range for candidates who will work in our South San Francisco location is between $35-$45 per hour.

Schedule

• Not specified.

Company Description

ORIC Pharmaceuticals is a clinical stage biopharmaceutical company dedicated to improving patients’ lives by Overcoming Resistance In Cancer. ORIC’s clinical stage product candidates include (1) ORIC-944, an allosteric inhibitor of the polycomb repressive complex 2 (PRC2) via the EED subunit, being developed for prostate cancer, and (2) ORIC-114, a brain penetrant inhibitor that selectively targets EGFR exon 20, HER2 exon 20 and EGFR atypical mutations, being developed across multiple genetically defined cancers. Beyond these two product candidates, ORIC® is also developing multiple precision medicines targeting other hallmark cancer resistance mechanisms. ORIC has offices in South San Francisco and San Diego, California. For more information, please go to www.oricpharma.com, and follow us on X or LinkedIn.